Literature DB >> 22310235

What is the role of family in promoting faecal occult blood test screening? Exploring physician, average-risk individual, and family perceptions.

Michelle M Lobchuk1, Sunita B Bapuji, Susan E McClement, Jeffrey J Sisler, Alan Katz, Patricia Martens, Donna Turner, Kathleen Clouston.   

Abstract

BACKGROUND: Although the number of Canadians being screened for colon cancer is rising, only 40% of Canadians aged 50 years or older reported they had engaged in faecal occult blood test (FOBT) screening as recommended. The notion of 'partnerships' that is inclusive of physicians, individuals at average-risk for colorectal cancer, and influential family members is receiving more attention in primary health care literature and policy on promoting health maintenance behaviours. To the best of our knowledge there are no studies that have taken a tripartite approach in describing perspectives of these three key stakeholders on the role of family in promoting adherence to FOBT. The aim of this study was to address the gap in understanding the perspectives of primary care physicians, individuals at average-risk for colorectal cancer, and family on family role in promoting adherence to FOBT screening.
METHOD: We employed a qualitative design and conducted semi-structured interviews with 15 physicians, 27 patients at average-risk for colorectal cancer, and 19 family members or friends from urban and rural Manitoba, Canada between October 2008 and March 2010. Interviews were audio-recorded, transcribed verbatim, and analysed using content analysis and constant comparative techniques.
RESULTS: While physicians described a clear role for family in managing chronic disease or dealing with acute or serious illness, they identified barriers in working with family to promote FOBT screening: lack of time, privacy and confidentiality concerns, and family dynamics. Conversely, patients and family described instrumental, emotional, informational, and appraisal roles that family play in promoting FOBT outside medical encounters.
CONCLUSION: Adherence to colorectal cancer screening is based on supportive 'patient-physician' dialogue that is separate from assistive 'patient-family member' relations. Further research is required to explore social support mechanisms involving family members outside medical encounters that hold promise in boosting self-efficacy, overcoming barriers, and gaining positive reinforcement for individuals at average-risk when making the decision to engage in FOBT.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22310235     DOI: 10.1016/j.canep.2012.01.002

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  4 in total

1.  Effectiveness and Cost of Implementing Evidence-Based Interventions to Increase Colorectal Cancer Screening Among an Underserved Population in Chicago.

Authors:  Karen E Kim; Florence K L Tangka; Manasi Jayaprakash; Fornessa T Randal; Helen Lam; David Freedman; Laurie A Carrier; Coletta Sargant; Chieko Maene; Sonja Hoover; Djenaba Joseph; Cynthia French; Sujha Subramanian
Journal:  Health Promot Pract       Date:  2020-09-29

2.  Waiting for diagnostic colonoscopy: a qualitative exploration of screening participants' experiences in a FIT-based colorectal cancer screening program.

Authors:  Pia Kirkegaard; Adrian Edwards; Mette Bach Larsen; Berit Andersen
Journal:  Patient Prefer Adherence       Date:  2018-05-17       Impact factor: 2.711

3.  A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK.

Authors:  Alan White; Lucy Ironmonger; Robert J C Steele; Nick Ormiston-Smith; Carina Crawford; Amanda Seims
Journal:  BMC Cancer       Date:  2018-09-20       Impact factor: 4.430

Review 4.  Screening for colorectal cancer: the role of the primary care physician.

Authors:  John K Triantafillidis; Constantine Vagianos; Aristofanis Gikas; Maria Korontzi; Apostolos Papalois
Journal:  Eur J Gastroenterol Hepatol       Date:  2017-01       Impact factor: 2.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.